Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
-Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis-
Stay updated with breaking news from Chris Erdman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis-
-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis - -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- ...
Earlier this month, friends and supporters of YoloCares gathered at Park Winters Estate for the annual Luminaries of Life Gala which raised $50,000.
26.09.2023 - WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) - Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence. Dr. Tipirneni is ...
WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen...